OPCH Option Care Health, Inc. Insider Trading

Director Timothy Sullivan buys ~24K shares at depressed valuations amid broader insider buying cluster.

Timothy P Sullivan, a director at Option Care Health, purchased a substantial stake representing nearly half his existing holdings at a time when the stock trades well below its recent highs, suggesting he sees value in the pullback. The company itself remains fundamentally sound — profitable with growing revenue — making this not a rescue bid for a struggling business but rather a conviction buy during a price dislocation. Sullivan's own track record on this stock shows he has timed prior purchases well, with shares rising after his last buy, lending credibility to his current judgment. The purchase also occurs within a window where two other insiders bought as well, indicating that this isn't an isolated director's gamble but part of a coordinated pattern of insider confidence in the stock's trajectory.

Director Harry M. Jansen Jr. Kraemer purchases over 36,600 shares of OPCH in open market amid significant stock decline.

Harry M. Jansen Jr. Kraemer, a director at Option Care Health, deployed nearly $784,000 to purchase over 36,600 shares at market prices while the stock has retreated substantially from its recent highs and has fallen sharply over the past three months. What makes this trade noteworthy is the timing: Kraemer is buying aggressively into weakness rather than during periods of price strength, which is the classic hallmark of insider conviction that the market has overreacted to recent headwinds. The company remains profitable with growing revenue and is trading at a reasonable valuation multiple, suggesting the fundamentals have not deteriorated despite the stock's recent decline. This director's willingness to increase his stake significantly at these depressed levels—without the vesting or exercise complications that can cloud many insider trades—suggests he views the pullback as a genuine opportunity rather than a sign of deeper trouble ahead.

CEO John Rademacher purchases 12,500 shares of OPCH amid sharp recent decline from highs.

CEO John Rademacher is buying Option Care Health stock after a significant pullback from its highs, reducing his exposure to equity losses and signaling confidence in the company's recovery potential. The timing is notable: the stock has declined sharply from its recent peak, yet Rademacher is deploying capital into the company he runs, which typically reflects insider conviction that the selloff is overdone. Option Care Health remains profitable with solid revenue growth, so Rademacher isn't catching a broken business—he's buying into a fundamentally sound operator during a weakness. This kind of C-suite buying during pullbacks is a credible signal of management's belief in value, though a single purchase by one executive is less powerful than a coordinated wave of insider accumulation.

CFO Meenal's first open-market purchase in 3 years marks a regime shift from seller to buyer as stock falls sharply from 52-week highs.

Sethna Meenal, the CFO of Option Care Health, is purchasing shares for the first time on the open market in the past three years—a meaningful departure from a prior pattern of net selling. This purchase arrives as the stock trades roughly halfway down from its 52-week high, having declined substantially over the past quarter. The company itself remains profitable with solid revenue growth, suggesting that Meenal is buying weakness in a fundamentally sound business rather than catching a falling knife. This purchase is part of a broader wave, with three insiders buying within a two-week window—a pattern worth tracking. The shift from seller to buyer by the CFO, combined with deteriorating near-term price action, invites scrutiny into whether management sees value being created below current levels or if other factors are driving the activity.

Director Kraemer buys 38,000 OPCH shares at $25.98; holdings increase 10.1% to 413,390 shares.

Director Kraemer purchased 38,000 shares at $25.98 on 2025-11-03, expanding his position by 10.1% to 413,390 shares total, representing a $987,392.00 commitment. At the current price of $27.03, the stock trades -23.2% below its 52-week high of $35.20. His prior four trades at Option Care Health show a mixed timing record: one measurable 90-day outcome was well-timed (the 2024-11-08 buy, which returned +36.8%), while three others showed negative 90-day returns (-8.0%, -18.5%, and one not yet measurable). The company shows solid fundamentals with $1.4B quarterly revenue, $51.8M net income, and annual growth of +16.2%, though the current P/E of 20.48 reflects elevated valuations. The 10.1% increase in holdings is material and suggests continued engagement with the stock at levels below historical highs.

Director Wright buys 3,411 shares of OPCH at $29.31, increasing stake 28.2% to 15,501 shares totaling $100.0K

Director Norman L. Wright purchased 3,411 shares at $29.31 on 2025-09-09, expanding his position by 28.2% from 12,090 to 15,501 shares. The transaction occurred at a price 2.1% above the current price of $28.70 and 16.8% below the 52-week high of $35.20, placing it in the middle of the stock's recent trading range. Option Care Health trades at a P/E of 22.08 with strong fundamentals: annual revenue growth of 16.2% and latest-quarter revenue of $1.4B generating net income of $50.5M. The open-market purchase reflects Wright's willingness to commit capital to increase his ownership stake in a company operating in a growing healthcare sector.

Director Timothy Sullivan buys 20,000 OPCH shares at $27.51; holdings increase 68.4% amid 3-stock insider cluster buy within 14 days.

Director Timothy Sullivan purchased 20,000 shares ($550,200.00 total value) on 2025-08-21 at $27.51, raising his stake from 29,229 to 49,229 shares—a 68.4% increase in his holdings. This buy occurred as part of a cluster pattern: 3 other insiders also purchased within the past 14 days, suggesting coordinated director-level accumulation activity. The stock is currently trading at $27.84, down 20.9% from its 52-week high and off 6.5% over the past 30 days, providing context for the timing of this purchase. Notably, Sullivan's prior trade at OPCH (a sell on 2024-08-22) was well-timed at the 90-day mark, indicating a track record of disciplined transaction execution at this ticker, though the current buy's forward-looking merit remains to be established.

Director Pate R Carter bought 750 OPCH shares at $27.19; stock now $27.84, down -20.9% from 52-week high. Cluster buy pattern (3 other insiders also bought within 14 days).

Pate R Carter, a Director, purchased 750 shares of Option Care Health at $27.19 on 2025-08-20, increasing his holdings from 41,160 to 41,910 shares (41.9K shares). The stock is currently trading at $27.84, approximately at the transaction price, but remains -20.9% from its 52-week high of $35.20 and has declined -6.5% over the past 30 days. His cross-ticker track record shows 2 prior buys with a 0.00% 90-day win rate and an average 90-day return of -15.7%; at OPCH specifically, a prior August 2023 purchase returned -14.2% over 90 days. More significantly, this purchase is part of a broader cluster pattern: 3 other insiders also bought within the past 14 days, suggesting a coordinated or signal-aligned buying window. The company's fundamentals are solid—$1.4B in latest quarterly revenue with +16.2% annual growth, $50.5M net income, and a P/E of 21.42—but the stock's recent downtrend and the insider's weak historical timing on similar purchases merit attention.

Director Golding buys 1,000 shares of OPCH at $27.62; 3 other insiders bought within 14 days as stock down 20.9% from 52-week high

David W. Golding, Director, purchased 1,000 shares at $27.62, adding to holdings of 116,525 shares post-transaction. This buy coincides with a cluster pattern: 3 other insiders also acquired shares within the past 14 days. The timing is notable relative to price context—the stock trades at $27.84, down 20.9% from its 52-week high of $35.20 and down 6.5% over the past 30 days. Despite the recent weakness, the company shows solid fundamentals with annual revenue growth of 16.2%, a P/E of 21.42, and net income of $50,523,000.00 last quarter. The convergence of multiple insider purchases at depressed price levels within a short window is a pattern worth monitoring, though the absolute transaction size ($27,625.00) remains modest relative to company scale ($4.5B market cap).

Director Kraemer buys 36,000 OPCH shares at $27.15; stock -20.9% from 52-week high; 3 other insiders also bought within 14 days.

Director Harry M Jansen Jr Kraemer purchased 36,000 shares of Option Care Health at $27.15 on 2025-08-20, increasing his holdings by 10.6% to 375,390 shares, representing a $977.3K investment. The buy occurs with the stock trading -20.9% from its 52-week high of $35.20 and down -6.5% over the past 30 days, while the company shows solid fundamentals with $1.4B in quarterly revenue, +16.2% annual growth, and $50.5M net income. His prior OPCH transaction history is mixed: one well-timed buy on 2024-11-08 that returned +36.8% at 90 days, but two poorly-timed buys in 2024 and 2023 that underperformed or declined. A cluster of 3 other insiders also buying within the past 14 days adds a multi-director buy signal, though the insider's own track record at this ticker shows only 33% alignment with strong 90-day returns.